Quotient Sciences Header

Quotient Sciences Header

X

Find Gastroenterology Drugs in Phase II/III Clinical Development in IRELAND

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Allergan Plc","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Allergan Plc"},{"company":"Allergan Plc","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Regains Global Rights to Brazikumab From Allergan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Allergan Plc"}]

Allergan Plc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AstraZeneca Regains Global Rights to Brazikumab From Allergan

Details:

AstraZeneca and Allergan have terminated their previous license agreement and all rights to brazikumab have therefore now returned to AstraZeneca.

Lead Product(s): Brazikumab

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 11, 2020

ASK
US

Upload
your Pipeline Activity

Allergan Plc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

Details:

AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

Lead Product(s): Brazikumab

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Divestment January 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY